Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14 –skipping mutation: A series of 6 cases

The prognosis of advanced non-small –cell lung cancer (NSCLC) has been dramatically improved by promising new treatments: targeted therapies for oncogenic addictions and immune-checkpoint inhibitors (ICIs), including anti-programmed cell-death protein-1 (PD-1) nivolumab and pembrolizumab.

Source: Lung Cancer - September 15, 2020 Category: Cancer & Oncology Authors: Marie Mayenga, Jean-Baptiste Assi é, Isabelle Monnet, Marie-Ange Massiani, Laure Tabeze, Sylvie Friard, Séverine Fraboulet, Anne-Cécile Métivier, Christos Chouaïd, Leïla Zemoura, Elisabeth Longchampt, Céline Callens, Samia Melaabi, Louis-Jean Coude Source Type: research